December 02, 2014 12:24 am | Updated April 07, 2016 02:22 am IST - NEW DELHI:
Ranbaxy Laboratories on Monday launched the first biosimilar version of Johnson and Johnson’s Remicade, a drug used for treating various conditions including rheumatoid arthritis. Infimab has been introduced in the domestic market through a licensing partnership with Epirus Biopharmaceuticals, Ranbaxy said in a statement. Infimab will be manufactured by Reliance Life Sciences at its facility in Mumbai, it added.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
